adplus-dvertising
Connect with us

Investment

Infographic: Investment Opportunities in Biotech

Published

 on

Graphics & Design

Infographic: Investment Opportunities in Biotech

With the world evolving at an unprecedented pace, nearly every sector is being disrupted in some way or another.

In transportation, EVs were spearheaded by Tesla, which emerged as the first new American automaker in decades, and is now one of the world’s most valuable companies. Similarly, in the realm of AI, OpenAI has taken a leading position in large language models, demonstrating the immense potential of the technology.

Now, we turn our attention to biotech, an industry that is developing innovative treatments at an accelerated pace. In this graphic from sponsor MSCI, we explain the growing pipeline of biotech treatments, and why this could benefit investors.

Growth in Clinical Drug Trials

A clinical drug trial is a study performed on people to evaluate the effectiveness of a medical intervention. Since 2000, the number of trials initiated annually has grown by over 1,300%.

Drug Trial Type 2000 2010 2020 2022
Monoclonal antibody 60 623 1,833 1,685
Protein & peptide therapeutics 172 1,058 1,771 1,567
Vaccine 80 594 1,259 915
Recombinant antibody 50 513 984 860
Cell therapy 56 277 548 502
Gene-Modified Cell Therapy 16 148 355 423
DNA & RNA therapeutics 7 56 475 346
Other biotechnology product 28 236 362 347
Total 469 3,505 7,587 6,645

Behind every new treatment is an innovative company working to develop it. Thus, as the number of clinical trials grows, so too does the size of the investment universe.

Unfortunately, identifying suitable companies for investment is rather difficult. While a disease may have thousands of potential medicines, only one may ultimately receive FDA approval. This approval process can also take over a decade because treatments must pass several phases of testing.

Introducing the MSCI Life Sciences Indexes

To capture investment opportunities in biotech, MSCI has released a suite of thematic indexes that focus on key growth categories such as oncology and virology.

Developed in collaboration with Royalty Pharma, the world’s largest buyer of pharmaceutical royalties, the MSCI Life Sciences Indexes are designed to gauge the performance of pioneering companies within the biotech space.

These unique indexes can be used to benchmark growth, facilitate portfolio construction, and enhance investment research.

 

728x90x4

Source link

Continue Reading

Economy

S&P/TSX composite down more than 200 points, U.S. stock markets also fall

Published

 on

 

TORONTO – Canada’s main stock index was down more than 200 points in late-morning trading, weighed down by losses in the technology, base metal and energy sectors, while U.S. stock markets also fell.

The S&P/TSX composite index was down 239.24 points at 22,749.04.

In New York, the Dow Jones industrial average was down 312.36 points at 40,443.39. The S&P 500 index was down 80.94 points at 5,422.47, while the Nasdaq composite was down 380.17 points at 16,747.49.

The Canadian dollar traded for 73.80 cents US compared with 74.00 cents US on Thursday.

The October crude oil contract was down US$1.07 at US$68.08 per barrel and the October natural gas contract was up less than a penny at US$2.26 per mmBTU.

The December gold contract was down US$2.10 at US$2,541.00 an ounce and the December copper contract was down four cents at US$4.10 a pound.

This report by The Canadian Press was first published Sept. 6, 2024.

Companies in this story: (TSX:GSPTSE, TSX:CADUSD)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Economy

S&P/TSX composite up more than 150 points, U.S. stock markets also higher

Published

 on

 

TORONTO – Canada’s main stock index was up more than 150 points in late-morning trading, helped by strength in technology, financial and energy stocks, while U.S. stock markets also pushed higher.

The S&P/TSX composite index was up 171.41 points at 23,298.39.

In New York, the Dow Jones industrial average was up 278.37 points at 41,369.79. The S&P 500 index was up 38.17 points at 5,630.35, while the Nasdaq composite was up 177.15 points at 17,733.18.

The Canadian dollar traded for 74.19 cents US compared with 74.23 cents US on Wednesday.

The October crude oil contract was up US$1.75 at US$76.27 per barrel and the October natural gas contract was up less than a penny at US$2.10 per mmBTU.

The December gold contract was up US$18.70 at US$2,556.50 an ounce and the December copper contract was down less than a penny at US$4.22 a pound.

This report by The Canadian Press was first published Aug. 29, 2024.

Companies in this story: (TSX:GSPTSE, TSX:CADUSD)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Investment

Crypto Market Bloodbath Amid Broader Economic Concerns

Published

 on

Breaking Business News Canada

The crypto market has recently experienced a significant downturn, mirroring broader risk asset sell-offs. Over the past week, Bitcoin’s price dropped by 24%, reaching $53,000, while Ethereum plummeted nearly a third to $2,340. Major altcoins also suffered, with Cardano down 27.7%, Solana 36.2%, Dogecoin 34.6%, XRP 23.1%, Shiba Inu 30.1%, and BNB 25.7%.

The severe downturn in the crypto market appears to be part of a broader flight to safety, triggered by disappointing economic data. A worse-than-expected unemployment report on Friday marked the beginning of a technical recession, as defined by the Sahm Rule. This rule identifies a recession when the three-month average unemployment rate rises by at least half a percentage point from its lowest point in the past year.

Friday’s figures met this threshold, signaling an abrupt economic downshift. Consequently, investors sought safer assets, leading to declines in major stock indices: the S&P 500 dropped 2%, the Nasdaq 2.5%, and the Dow 1.5%. This trend continued into Monday with further sell-offs overseas.

The crypto market’s rapid decline raises questions about its role as either a speculative asset or a hedge against inflation and recession. Despite hopes that crypto could act as a risk hedge, the recent crash suggests it remains a speculative investment.

Since the downturn, the crypto market has seen its largest three-day sell-off in nearly a year, losing over $500 billion in market value. According to CoinGlass data, this bloodbath wiped out more than $1 billion in leveraged positions within the last 24 hours, including $365 million in Bitcoin and $348 million in Ether.

Khushboo Khullar of Lightning Ventures, speaking to Bloomberg, argued that the crypto sell-off is part of a broader liquidity panic as traders rush to cover margin calls. Khullar views this as a temporary sell-off, presenting a potential buying opportunity.

Josh Gilbert, an eToro market analyst, supports Khullar’s perspective, suggesting that the expected Federal Reserve rate cuts could benefit crypto assets. “Crypto assets have sold off, but many investors will see an opportunity. We see Federal Reserve rate cuts, which are now likely to come sharper than expected, as hugely positive for crypto assets,” Gilbert told Coindesk.

Despite the recent volatility, crypto continues to make strides toward mainstream acceptance. Notably, Morgan Stanley will allow its advisors to offer Bitcoin ETFs starting Wednesday. This follows more than half a year after the introduction of the first Bitcoin ETF. The investment bank will enable over 15,000 of its financial advisors to sell BlackRock’s IBIT and Fidelity’s FBTC. This move is seen as a significant step toward the “mainstreamization” of crypto, given the lengthy regulatory and company processes in major investment banks.

The recent crypto market downturn highlights its volatility and the broader economic concerns affecting all risk assets. While some analysts see the current situation as a temporary sell-off and a buying opportunity, others caution against the speculative nature of crypto. As the market evolves, its role as a mainstream alternative asset continues to grow, marked by increasing institutional acceptance and new investment opportunities.

Continue Reading

Trending